Nektar Therapeutics reported $14.46M in Stock for its fiscal quarter ending in June of 2024.





Stock Change Date
Agios Pharmaceuticals USD 37.84M 2.09M Sep/2026
ALKERMES USD 261.1M 37.86M Sep/2026
Amgen USD 6.39B 169M Sep/2026
Baxter International USD 2.3B 41M Sep/2026
BioCryst Pharmaceuticals USD 13.74M 7.68M Sep/2026
Biogen USD 2.22B 159.9M Sep/2026
Bristol-Myers Squibb USD 2.7B 33M Sep/2026
Cara Therapeutics USD 900K 0 Mar/2025
Cipla INR 67.78B 1.82B Sep/2026
Dr.Reddys Laboratories INR 80.47B 3.94B Jun/2026
Eisai JPY 272.61B 15.06B Sep/2026
Eli Lilly USD 18.19B 1.4B Sep/2026
Exelixis USD 29.87M 1.14M Sep/2026
Gilead Sciences USD 1.9B 57M Sep/2026
GlaxoSmithKline GBP 6.28B 125M Jun/2026
Grifols EUR 3.56B 63.19M Dec/2024
Halozyme Therapeutics USD 132.61M 4.52M Sep/2026
Incyte USD 134.25M 21.71M Sep/2026
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
MacroGenics USD 9.5M 1.59M Mar/2026
Merck USD 6.16B 43M Sep/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 66.1M 38.1M Sep/2026
Novartis USD 6.1B 116M Sep/2026
Pfizer USD 10.02B 77M Sep/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
Takeda JPY 1.44T 6.17B Sep/2026
Teva Pharmaceutical Industries USD 3.17B 48M Sep/2026